Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinoteca... von Duffy, A.G., Makarova‐Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi‐Jaoudeh, N., Levy, E., Wood, B.J., Lee, S., Tomita, Y., Trepel, J.B., Steinberg, S.M., Revenko, A.S., MacLeod, A.R., Peer, C.J., Figg, W.D., Greten, T.F.

Volltext

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib von Duffy, AG, Ulahannan, SV, Cao, L, Rahma, OE, Makarova-Rusher, OV, Kleiner, DE, Fioravanti, S, Walker, M, Carey, S, Yu, Y, Venkatesan, AM, Turkbey, B, Choyke, P, Trepel, J, Bollen, KC, Steinberg, SM, Figg, WD, Greten, TF

Volltext

2259 Tremelimumab - A monoclonal antibody against CTLA-4 - in combination with local tumor ablation (TACE or RFA) in patients with hepatocellular carcinoma (HCC) von Greten, T, Duffy, A, Rusher, O, Kerkar, S, Kleiner, D, Figg, W, Steinberg, S, Abi-Jaoudeh, N, Wood, B

Volltext